The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
EditorialsFull Access

Looking Through a Fog: What Persistent Derealization Can Teach Us About PTSD

Clinicians and researchers in psychiatry have long sought to identify specific variables that predict important constructs related to clinical care, such as response to treatment, the course of a disorder, and the risk of developing a disorder. Indeed, interest in such predictors has grown as the field has moved toward precision psychiatry (13). The benefits of prediction are clear; for example, the ability to predict response to a particular treatment would help to expedite the amelioration of symptoms by bypassing the often slow trial-and-error process of finding an effective treatment. In addition, the ability to predict risk for a disorder would help identify individuals who might benefit from interventions that prevent or decrease the severity of a disorder (4). In this issue of the Journal, Lebois et al. (5) used clinical and biological measures to predict the severity of posttraumatic stress disorder (PTSD) symptoms and other psychiatric outcomes following exposure to a traumatic event.

Variables that are known to indicate heightened risk for PTSD include sex/gender, history of previous trauma, family or personal history of psychopathology, and peritraumatic dissociation (69). In addition, researchers have started to examine neuroimaging variables that may likewise indicate risk for PTSD, such as hippocampal volume or activation of the amygdala or medial prefrontal cortex (1014). Because the majority of people who are exposed to trauma do not develop PTSD, studies of predictors of PTSD benefit from having large samples of trauma-exposed participants. Given its inclusion of both clinical and neuroimaging variables and its relatively large sample size, the Lebois et al. study is an important investigation of the predictors of PTSD symptoms following trauma. Adding to the novelty of the study, these researchers decided to investigate a specific subtype of dissociation that may predict subsequent PTSD symptoms—persistent derealization, which is marked by feeling that one’s surroundings seem strange or unreal and/or that one is looking through a fog so that people or things seem far away or unclear.

Lebois and colleagues examined whether self-reported persistent derealization and its neural correlates, measured shortly after a traumatic event, can predict PTSD symptom severity and other clinical outcomes 3 months after the trauma. The authors analyzed data from the AURORA study (15), which included individuals who had visited an emergency department in the United States following a traumatic event such as a motor vehicle collision or a physical assault. In the Lebois et al. study, participants provided ratings of persistent derealization (N=1,464) and underwent functional MRI (fMRI) scanning (N=145) approximately 2 weeks after the traumatic event. Three months after the trauma, participants completed assessments of their psychiatric symptoms, pain, and level of impairment. The authors found that at 2 weeks posttrauma, persistent derealization severity was positively correlated with ventromedial prefrontal cortex (vmPFC) activation in response to fearful versus neutral facial expressions, even after controlling for potential confounders. Most importantly, in separate regression analyses, both persistent derealization severity and vmPFC activation positively predicted PTSD symptom severity 3 months posttrauma, even after controlling for age, sex, childhood maltreatment severity, and 2-week PTSD symptom severity. These findings suggest that assessing self-reported persistent derealization or vmPFC activation shortly after trauma exposure could be helpful in predicting PTSD symptoms later.

Readers may wonder which of these two variables is the better predictor of PTSD symptoms. Although the variables’ relative predictive strength was not assessed within a single regression, presumably because they were correlated with each other, the regression that included persistent derealization did explain a greater proportion of the variance in PTSD symptoms than did the regression that included vmPFC activation. Many readers will argue, compellingly, that when it comes to predicting PTSD symptoms, administering a two-item self-report measure of persistent derealization is far more efficient, cost-effective, and inclusive than conducting a specialized and expensive fMRI scan that is unlikely to be available to everyone. Why, then, should we even consider neuroimaging variables as predictors of PTSD symptoms? One potential benefit of doing so is to identify possible brain regions or circuits that may be viable targets for intervention. For example, the results of this and other studies suggest that the vmPFC is a reasonable target for transcranial magnetic stimulation (TMS) or its variants (e.g., intermittent theta burst stimulation [iTBS]). Even if the vmPFC itself is too ventral to target directly with TMS, functional connectivity analyses conducted in individual patients can reveal cortical regions that are tightly functionally correlated (or anticorrelated) with the vmPFC but are more dorsal and hence more easily reached with TMS. In short, the vmPFC can be reached at least indirectly by TMS or iTBS, and this personalized approach has been used successfully to treat depression (16).

The findings of Lebois and colleagues are certainly exciting for their potential clinical relevance and contributions to neurocircuitry models of PTSD. Nevertheless, they also need to be replicated in a large, independent sample in order to more thoroughly assess the prediction accuracy of the variables studied (1). In addition, it will be helpful to know whether other types of dissociation and activation in other subregions of the vmPFC similarly predict outcome. Finally, in order to better understand the origins of these predictors of PTSD symptoms, it will be important for future studies to determine whether persistent derealization and exaggerated vmPFC activation are trait-like vulnerability factors that are present even before trauma exposure, which could be helpful in identifying potential candidates for primary prevention efforts.

Department of Psychology, Tufts University, Medford, Mass.; Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston.
Send correspondence to Dr. Shin ().

Dr. Shin receives textbook-related royalties from Pearson.

References

1. Fusar-Poli P, Hijazi Z, Stahl D, et al.: The science of prognosis in psychiatry: a review. JAMA Psychiatry 2018; 75:1289–1297Crossref, MedlineGoogle Scholar

2. Meehan AJ, Lewis SJ, Fazel S, et al.: Clinical prediction models in psychiatry: a systematic review of two decades of progress and challenges. Mol Psychiatry 2022; 27:2700–2708Crossref, MedlineGoogle Scholar

3. Paulus MP: Pragmatism instead of mechanism: a call for impactful biological psychiatry. JAMA Psychiatry 2015; 72:631–632Crossref, MedlineGoogle Scholar

4. Bernardini F, Attademo L, Cleary SD, et al.: Risk prediction models in psychiatry: toward a new frontier for the prevention of mental illnesses. J Clin Psychiatry 2017; 78:572–583Crossref, MedlineGoogle Scholar

5. Lebois LAM, Harnett NG, van Rooij SJH: Persistent dissociation and its neural correlates in predicting outcomes after trauma exposure. Am J Psychiatry 2022; 179:661–672LinkGoogle Scholar

6. DiGangi JA, Gomez D, Mendoza L, et al.: Pretrauma risk factors for posttraumatic stress disorder: a systematic review of the literature. Clin Psychol Rev 2013; 33:728–744Crossref, MedlineGoogle Scholar

7. Ozer EJ, Best SR, Lipsey TL, et al.: Predictors of posttraumatic stress disorder and symptoms in adults: a meta-analysis. Psychol Bull 2003; 129:52–73Crossref, MedlineGoogle Scholar

8. Tortella-Feliu M, Fullana MA, Perez-Vigil A, et al.: Risk factors for posttraumatic stress disorder: an umbrella review of systematic reviews and meta-analyses. Neurosci Biobehav Rev 2019; 107:154–165Crossref, MedlineGoogle Scholar

9. Xue C, Ge Y, Tang B, et al.: A meta-analysis of risk factors for combat-related PTSD among military personnel and veterans. PLoS One 2015; 10:e0120270Crossref, MedlineGoogle Scholar

10. Admon R, Lubin G, Stern O, et al.: Human vulnerability to stress depends on amygdala’s predisposition and hippocampal plasticity. Proc Natl Acad Sci U S A 2009; 106:14120–14125Crossref, MedlineGoogle Scholar

11. Gilbertson MW, Shenton ME, Ciszewski A, et al.: Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 2002; 5:1242–1247Crossref, MedlineGoogle Scholar

12. McLaughlin KA, Busso DS, Duys A, et al.: Amygdala response to negative stimuli predicts PTSD symptom onset following a terrorist attack. Depress Anxiety 2014; 31:834–842Crossref, MedlineGoogle Scholar

13. Shin LM, Lasko NB, Macklin ML, et al.: Resting metabolic activity in the cingulate cortex and vulnerability to posttraumatic stress disorder. Arch Gen Psychiatry 2009; 66:1099–1107Crossref, MedlineGoogle Scholar

14. Shin LM, Bush G, Milad MR, et al.: Exaggerated activation of dorsal anterior cingulate cortex during cognitive interference: a monozygotic twin study of posttraumatic stress disorder. Am J Psychiatry 2011; 168:979–985LinkGoogle Scholar

15. McLean SA, Ressler K, Koenen KC, et al.: The AURORA study: a longitudinal, multimodal library of brain biology and function after traumatic stress exposure. Mol Psychiatry 2020; 25:283–296Crossref, MedlineGoogle Scholar

16. Cole EJ, Phillips AL, Bentzley BS, et al.: Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry 2022; 179:132–141LinkGoogle Scholar